884495-41-4

Basic information

• Product Name: 2,3-Dichloropyridine-4-carboxaldehyde
• Synonyms: 2,3-Dichloropyridine-4-carboxaldehyde;2,3-dichloroisonicotinaldehyde;2,3-Dichloro-4-pyridinecarboxaldehyde;2,3-dichloro-5-forMylpyridine-4-carboxylic acid;2,3-dichloropyridine-4-carbaldehyde
• CAS NO: 884495-41-4
• Molecular Formula: C₆H₃Cl₂NO
• Molecular Weight: 176.00012
• Product Categories: Pyridine;Pyridines
• Mol File: 884495-41-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 94-96°
• Boiling Point: 262℃
• Flash Point: 112℃
• Appearance: /
• Density: 1.488
• Vapor Pressure: 0.061mmHg at 25°C
• Refractive Index: 1.537
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.00±0.10(Predicted)
• CAS DataBase Reference: 2,3-Dichloropyridine-4-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Dichloropyridine-4-carboxaldehyde(884495-41-4)
• EPA Substance Registry System: 2,3-Dichloropyridine-4-carboxaldehyde(884495-41-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 884495-41-4(Hazardous Substances Data)

Usage

Description

2,3-Dichloropyridine-4-carboxaldehyde is an organic compound characterized by the presence of two chlorine atoms at the 2nd and 3rd positions of the pyridine ring and a formyl group (aldehyde) at the 4th position. This chemical structure endows it with unique properties that make it a versatile intermediate in organic synthesis and a potential candidate for various applications in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
2,3-Dichloropyridine-4-carboxaldehyde is used as a key intermediate in the synthesis of Shp2 phosphatase inhibitors. These inhibitors are being developed for the treatment of disorders associated with SHP2 deregulation, which plays a crucial role in various cellular processes, including cell growth, differentiation, and immune response. By targeting Shp2, these inhibitors can potentially modulate these processes and offer therapeutic benefits in treating related diseases.
Used in Organic Synthesis:
2,3-Dichloropyridine-4-carboxaldehyde serves as a valuable building block in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its reactivity and functional groups allow for a wide range of chemical transformations, making it a useful component in the development of new molecules with desired properties and applications.

InChI:InChI=1/C6H5Cl2NO/c1-10-4-2-3-9-6(8)5(4)7/h2-3H,1H3

Upstream product

• 2402-77-9 2,3-dichloro-pyridine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1152617-79-2 2-[4-(2,3-dichloropyridin-4-ylmethyl)piperazin-1-yl]pyrimidine 
• 1152617-83-8 2,3-dichloro-4-(3H-spiro[2-benzofuran-1,4'-piperidine]-1'-yl)methylpyridine 
• 1254981-37-7 2,3-dichloro-4-[(4-phenyl-piperidin-1-yl)methyl]pyridine 
• 1257071-85-4 2,3-dichloro-4-(difluoromethyl)pyridine 
• 1257070-02-2 2,3-dichloroisonicotinaldehyde oxime 
• 184416-82-8 2,3-dichloroisonicotinonitrile 

Relevant articles and documents

1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.